drugset / Trial / NCT00106834

A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis

NCT00106834

Phase 3 Completed 378 enrolled Centocor, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine if infliximab (anti-TNF) is effective in the treatment of plaque psoriasis.

Timeline

Start
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications